CN1642554A - 作为ccr-3拮抗剂用于治疗炎症的吗啉脲衍生物苯磺酸盐 - Google Patents

作为ccr-3拮抗剂用于治疗炎症的吗啉脲衍生物苯磺酸盐 Download PDF

Info

Publication number
CN1642554A
CN1642554A CNA038073641A CN03807364A CN1642554A CN 1642554 A CN1642554 A CN 1642554A CN A038073641 A CNA038073641 A CN A038073641A CN 03807364 A CN03807364 A CN 03807364A CN 1642554 A CN1642554 A CN 1642554A
Authority
CN
China
Prior art keywords
formula
compound
compounds
mixture
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038073641A
Other languages
English (en)
Chinese (zh)
Inventor
J·S·库克
R·P·兰顿
A·J·瓦尔克
M·威尔金逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1642554A publication Critical patent/CN1642554A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA038073641A 2002-03-28 2003-03-27 作为ccr-3拮抗剂用于治疗炎症的吗啉脲衍生物苯磺酸盐 Pending CN1642554A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0207432.6 2002-03-28
GBGB0207432.6A GB0207432D0 (en) 2002-03-28 2002-03-28 Novel compounds

Publications (1)

Publication Number Publication Date
CN1642554A true CN1642554A (zh) 2005-07-20

Family

ID=9933984

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038073641A Pending CN1642554A (zh) 2002-03-28 2003-03-27 作为ccr-3拮抗剂用于治疗炎症的吗啉脲衍生物苯磺酸盐

Country Status (22)

Country Link
US (1) US7531651B2 (enExample)
EP (1) EP1487456B1 (enExample)
JP (1) JP2005526808A (enExample)
KR (1) KR20040099375A (enExample)
CN (1) CN1642554A (enExample)
AR (1) AR039179A1 (enExample)
AT (1) ATE317698T1 (enExample)
AU (1) AU2003226761A1 (enExample)
BR (1) BR0308480A (enExample)
CA (1) CA2479912A1 (enExample)
DE (1) DE60303603T2 (enExample)
ES (1) ES2258724T3 (enExample)
GB (1) GB0207432D0 (enExample)
IL (1) IL163847A0 (enExample)
IS (1) IS7432A (enExample)
MX (1) MXPA04009456A (enExample)
NO (1) NO20044323L (enExample)
PL (1) PL372623A1 (enExample)
RU (1) RU2004126948A (enExample)
TW (1) TW200407145A (enExample)
WO (1) WO2003082293A1 (enExample)
ZA (1) ZA200407463B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335083A1 (en) * 2011-12-01 2014-11-13 Glaxo Group Limited Methods of treatment and prevention of eye diseases
FR3022142B1 (fr) 2014-06-16 2019-07-12 Universite Paul Sabatier - Toulouse Iii Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031431A1 (en) 1994-05-18 1995-11-23 Nisshin Flour Milling Co., Ltd. Novel diaminomethylidene derivative
BR9915520A (pt) 1998-11-20 2001-07-17 Hoffmann La Roche Antagonistas receptores ccr-3 derivados de pirrolidina
IL155092A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
CA2479912A1 (en) 2003-10-09
IS7432A (is) 2004-08-31
EP1487456B1 (en) 2006-02-15
EP1487456A1 (en) 2004-12-22
GB0207432D0 (en) 2002-05-08
TW200407145A (en) 2004-05-16
ES2258724T3 (es) 2006-09-01
AU2003226761A1 (en) 2003-10-13
RU2004126948A (ru) 2005-07-10
IL163847A0 (en) 2005-12-18
WO2003082293A1 (en) 2003-10-09
US20060089497A1 (en) 2006-04-27
BR0308480A (pt) 2005-01-18
US7531651B2 (en) 2009-05-12
PL372623A1 (en) 2005-07-25
JP2005526808A (ja) 2005-09-08
ZA200407463B (en) 2005-10-12
DE60303603T2 (de) 2006-10-26
AR039179A1 (es) 2005-02-09
ATE317698T1 (de) 2006-03-15
NO20044323L (no) 2004-10-27
MXPA04009456A (es) 2005-01-25
DE60303603D1 (de) 2006-04-20
KR20040099375A (ko) 2004-11-26

Similar Documents

Publication Publication Date Title
CN1218940C (zh) 氧化氮合酶抑制剂
CN1227237C (zh) 作为五羟色胺5-ht2受体拮抗剂的哌嗪基吡嗪化合物
CN1319958C (zh) 作为血清素再摄取抑制剂的苯基哌嗪衍生物
CN1136219C (zh) 用于治疗阳痿的吡唑并嘧啶酮衍生物
CN1441785A (zh) 可用作生长激素促分泌素的四氢异喹啉类似物
CN1909897A (zh) 用于治疗阿尔茨海默病的苯基羧化物β-分泌酶抑制剂
CN1039910C (zh) 雪花胺衍生物、其制备方法及其作为药物的用途
CN1192144A (zh) 1h-4(5)-取代的咪唑衍生物
EA024716B1 (ru) Производные 5-(3-аминофенил)-5-алкил-5,6-дигидро-2h-[1,4]оксазин-3-амина
JP2010530874A (ja) 6,5−ピロロピペリジンタキキニン受容体アンタゴニスト
JP2007507504A (ja) フェニルピロリジンエーテル系タキキニン受容体拮抗薬
CN1229335C (zh) 莫维诺林衍生物
CN1109870A (zh) N-(3-氨基丙基)-n-苯基-5,6,7,8-四氢化萘-2-羧酰胺衍生物衍生物、制法及应用
JP2005526807A (ja) 炎症性症状の治療においてccr−3アンタゴニストとして使用するための、アリールアルキルウレア基により2位が置換されたモルホリン誘導体
CN1656097A (zh) 黄嘌呤磷酸二酯酶v抑制剂多晶型物
CN1056496A (zh) 麦角灵-8-羧基酰胺的改进及其有关方面
CN101052393A (zh) 氮杂双环己烷的新型多晶型物
CN1046517C (zh) 三唑并哒嗪,其制备和应用
CN1606557A (zh) 经氘代的吡唑嘧啶酮以及包含该化合物的药物组合物
CN1129697A (zh) 新的5-(芳氧基甲基)噁唑啉,其制备方法和含它们的药物组合物
CN1055472C (zh) 噁唑并喹啉酮衍生物,它们的制备及其在治疗上的应用
CN1642553A (zh) N -{ [ ( 2 s ) - 4 - ( 3 , 4-二氟苄基 )吗啉 - 2 -基}甲基} - 2 -{ 3 - [ (甲基磺酰基 )氨基 ]苯基}乙酰胺作为ccr3拮抗剂用于治疗炎症
EP1487456B1 (en) Benzenesulphonate salt of a morpholine urea derivative for use as a ccr-3 antagonist in the treatment of inflammatory conditions
CN1642928A (zh) 吗啉衍生物的制备方法及其中间体
JP2005529094A (ja) 炎症性疾患の治療に有用なccr−3拮抗薬としてのn−(モルホリン−2−イル)メチルアセトアミド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication